Summary:
- Thermo Fisher Scientific (TMO, Financial) beats earnings expectations with a Q1 Non-GAAP EPS of $5.15.
- Revenue reached $10.36 billion, marking a slight year-over-year increase.
- Analysts see potential upside with the stock's average target price suggesting significant growth.
Thermo Fisher Scientific Inc. (TMO) has demonstrated robust financial performance in the first quarter, reporting a Non-GAAP EPS of $5.15, which topped analyst expectations by $0.05. The company's revenue hit $10.36 billion, illustrating a modest increase of 0.1% compared to the previous year and exceeding analyst forecasts by $130 million. Notably, organic revenue experienced a 1% growth, showcasing the company's resilience. Investors should stay tuned as updated 2025 guidance will be revealed in the upcoming earnings call.
Wall Street Analysts Forecast
The outlook from 28 analysts is optimistic, with an average target price for Thermo Fisher Scientific Inc. set at $626.61. This projection includes a high estimate of $767.00 and a low of $475.00. The average target suggests a substantial 44.14% upside from the current trading price of $434.73. Investors can explore more detailed estimates on the Thermo Fisher Scientific Inc. (TMO, Financial) Forecast page.
Thermo Fisher Scientific enjoys a favorable consensus from brokerage firms, with an average recommendation score of 1.9, indicating an "Outperform" rating. This score, derived from 33 firms, falls within a scale where 1 signifies a Strong Buy, while 5 indicates a Sell.
According to GuruFocus estimates, the estimated GF Value for Thermo Fisher Scientific Inc. over the next year is pegged at $586.30. This valuation hints at a potential upside of 34.87% from the current stock price of $434.73. The GF Value reflects the stock's fair trading value, calculated using historical trading multiples, previous business growth, and projected business performance. For more in-depth data, visit the Thermo Fisher Scientific Inc. (TMO, Financial) Summary page.
